Andere Sprachen AIM Vaccine Co., Ltd.

Aktien

A3DV8Z

CNE100005KF2

6660

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:49 06.05.2024			% 5 Tage	% 1. Jan.
8.55 ^HKD	-3.72%		+2.03%	+8.92%

28.03.	Aim Vaccine reicht Voranträge für klinische Studien für zwei Impfstoffe ein; Aktien steigen um 3%	MT
28.03.	Verlust von Aim Vaccine vervierfacht sich im Jahr 2023 bei einem Umsatzrückgang von 6%; Aktien steigen um 3%	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%	28.03.
Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3%	28.03.
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for Haemophilus Influenzae Type B Conjugate Vaccine	28.03.
AIM Vaccine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
AIM Vaccine Co., Ltd. Submits the Pre- Application for Clinical Trials for quadrivalent influenza virus vaccine (MDCK Cells)	28.03.
Aim Vaccine Submits Clinical Trial's Pre-Application for Rabies Vaccine	27.03.
AIM Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Novel-Process Highly-Effective Human Diploid Rabies Vaccine	26.03.
AIM Vaccine Files Pre-Application for Marketing Registration of its Pneumonia Vaccine	05.03.
AIM Vaccine Boosts Development of Iterative Pneumonia Series Vaccines	04.03.
AIM Vaccine Expediting Development of Iterative Rabies Series Vaccines; Shares Drop 4%	04.03.
AIM Vaccine Advances Trial of Meningococcal Vaccine in China; Shares Fall 4%	04.03.
AIM Vaccine Expects Wider Loss in 2023; Shares Slide 4%	04.03.
AIM Vaccine Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine; Shares Fall 3%	04.03.
Aim Vaccine Co., Ltd. Initiation of Phase II Clinical Trial of Tetravalent Meningococcal Conjugate Vaccine	04.03.
AIM Vaccine Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	04.03.
Aim Vaccine Co., Ltd. Announces Completion of the Layout of Iterative Rabies Vaccine Products and Fully Advancing the Research and Development of the Product Series	04.03.
AIM Vaccine Co., Ltd. Announces Completion of Application for Marketing of 13-Valent Pneumonia Conjugate Vaccine, Iterative Serum-Free Rabies Vaccine and 23-Valent Pneumonia Polysaccharide Vaccine	04.03.
Aim Vaccine Co., Ltd. Submits Pre-Application for Clinical Trials for Absorbed Tetanus Vaccine	04.03.
AIM Vaccine Co., Ltd. Submits the Pre- Application for Marketing Registration for Its 13-Valent Pneumonia Conjugate Vaccine	01.03.
AIM Vaccine Co., Ltd. Announces Executive Changes	29.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen AIM Vaccine Co., Ltd.

Aktien

A3DV8Z

CNE100005KF2

6660

Andere Sprachen

Filter